Jazz, Valeant Pharmaceuticals International deal

Jazz granted VRX rights to market Xyrem sodium oxybate in Canada to treat cataplexy associated with narcolepsy. Jazz received an undisclosed upfront payment and is eligible for royalties. VRX expects Xyrem, which is approved in Canada, to launch mid-year. VRX markets Zelapar selegiline and Tasmar tolcapone to treat Parkinson's disease (PD), and the company's retigabine is in Phase III testing to treat partial onset epileptic seizures. ...